OS Therapies price target raised to $15 from $8 at Maxim

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive Phase 2b top-line data for OST-HER2 in recurrent osteosarcoma, meeting the primary endpoint of 12-month event free survival. The data now positions the company to meet with the FDA by the end of Q1 to discuss the potential for filing for accelerated approval, which would include comparison to a synthetic control already requested by the FDA and which OS Therapies has already started building, the analyst tells investors in a research note.